Brainsway

Brainsway has received FDA 510(k) clearance for three main indications: treatment-resistant major depressive disorder (MDD, 2013), obsessive-compulsive disorder (OCD, 2018), and cigarette smoking addiction (2020). The company also holds CE marking in Europe for several additional neuropsychiatric conditions. Each clearance covers the specific H-coil model and treatment protocol validated in pivotal trials.

Standard figure-8 TMS coils typically stimulate cortical tissue at depths of 1.5 to 2 cm below the skull. Brainsway's patented H-coil is designed to generate magnetic fields that stimulate deeper brain regions, reaching approximately 4 to 6 cm in depth, without requiring a higher surface electrical field. This allows non-invasive activation of limbic and reward-system structures that are inaccessible with conventional coils — a critical distinction in treating mood and addiction disorders.

Brainsway operates as a publicly traded medical device company, not an investment firm. Capital allocation decisions — including R&D spending, clinical trial funding, manufacturing expansion, and potential M&A — are made by CEO Yaacov Michlin and the executive leadership team, overseen by a board of directors chaired by David Zacut. As a commercial-stage company, Brainsway reinvests operating cash flow rather than deploying third-party investor capital.

Brainsway does not make fund commitments or direct investments as an allocator — it is an operating company that designs, manufactures, and sells medical devices. The question is misapplied; Brainsway is a Nasdaq-listed issuer, not an institutional LP. Its counterparties are hospitals, clinics, group purchasing organizations, and distributors rather than general partners or fund managers.

Brainsway does not have a posture on co-investments alongside GPs because it is not a capital allocator. The firm occasionally partners with academic medical centers and managed care organizations on investigator-sponsored clinical studies, which involve cost-sharing or grant funding, but these are operating partnerships rather than investment co-underwritings.